1) Thigpen JT, Blessing JA, DiSaia PJ, et al : A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma : a Gynecologic Oncology Group study. J Clin Oncol 12 : 1408─1414, 1994
2) Calero F, Asins─Codoner E, Jimeno J, et al : Epirubicin in advanced endometrial adenocarcinoma : a phaseII study of the Grupo Ginecologico Espanol para el tratamiento Oncologico(GGETO). Eur J Cancer 27 : 864─866, 1991
3) Thigpen JT, Blessing JA, Homesley H, et al : PhaseII trial of cisplatin as first─line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group Study. Gynecol Oncol 33 : 68─70, 1989
4) Van Wijk FH, Lhomme C, Bolis G, et al : PhaseII study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group. Eur J Cancer 39 : 78─85, 2003
5) Ball HG, Blessing JA, Lentz SS, et al : A phaseII trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium : a Gynecologic Oncology Group Study. Gynecol Oncol 62 : 278─281, 1996
6) Hirai Y, Hasumi K, Onose R, et al : PhaseII trial of 3─h infusion of paclitaxel in patientswith adenocarcinoma of endometrium : Japanese Multicenter Study Group. Gynecol Oncol 94 : 471─476, 2004
7) Katsumata N, Noda K, Nozawa S, et al : PhaseII trial of docetaxel in advanced or metastatic endometrial cancer : a Japanese Cooperative Study. British Journsl of Cancer 93 : 999─1004, 2005
8) Thigpen JT, Brady MF, Homesley H, et al : Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma : a Gynecologic Oncology Group Study. J Clin Oncol 22 : 3902─3908, 2004
9) Aapro MS, van Wijk FH, Bolis G, et al : Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma : definitive results of a randomized study(55872)by the EORTC Gynaecological Cancer Group. Ann Oncol 14 : 441─448, 2003
10) Fleming GF, Filiaci VL, Bentley RC, et al : Phase III randomized trial of doxorubicin+cisplatin versus doxorubicin+24─h paclitaxel+filgrastim in endometrial carcinoma : a Gynecologic Oncology Group Study. Ann Oncol 15 : 1173─1178, 2004
11) Fleming GF, Brunetto VL, Cella D, et al : PhaseIII trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma : a Gynecologic Oncology Group Study. J Clin Oncol 22 : 2159─2166, 2004
12) Lissoni A, Zanetta G, Losa G, et al : PhaseII study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol 7 : 861─863, 1996
13) Scudder SA, Liu PY, Smith HO, et al : Paclitaxel and carboplatin with amifostine in advanced or recurrent endometrial cancer : a Southwest Oncology Group trial. Proc ASCO 20 : 205a, 2001
14) Hoskins PJ, Swenerton KD, Pike JA, et al : Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer : A phaseII study. J Clin Oncol 19 : 4048─4053, 2001
15) Dimopoulos MA, Papadimitriou CA, Georgoulias V, et al : Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium : long─term results of a phaseII multicenter study. Gynecol oncol 78 : 52─57, 2000
16) Weber B, Mayer F, Bougnoux P, et al : What is the best chemotherapy regimen in recurrent or advanced endometrial carcinoma? Preliminary results. Proc Am Soc Clin Oncol 22 : 453, 2003
17) Lentz SS, Brady MF, Major FJ, et al : High dose megestrol acetate in advanced or recurrent endometrial carcinoma : a Gynecologic Oncology Group Study. J Clin Oncol 14 : 357─361, 1996
18) Moore TD, Phillips PH, Nerenstone SR, et al : Systemic treatment of advanced and recurrent endometrial carcinoma : current status and future directions. J Clin Oncol 9 : 1071─1088, 1991
19) Carlson JA Jr, Allegra JC, Day TG, et al : Tamoxifen and endometrial carcinoma : alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia. Am J Obstet Gynecol 149 : 149─153, 1984